Despite positive trial, Roche says Enspryng fell short of expectations in myasthenia gravis
21 Mar 2024
Phase 3Clinical ResultDrug Approval
Preview
Source: FiercePharma
Roche and Chugai's Enspryng won an original FDA approval in 2020 in neuromyelitis optica spectrum disorder.
Drug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is doing the opposite for its Enspryng study in the competitive autoimmune disorder of generalized myasthenia gravis (gMG).
Enspryng delivered a statistically significant benefit in improving symptoms and daily life metrics when used on top of standard-of-care therapy in gMG patients who are anti-AChR-seropositive, which represents about 80% of the disease population. The phase 3 LUMINESCE trial has met its primary endpoint as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at 24 weeks.
However, in announcing the positive readout, Roche’s Chugai said the degree of clinical benefit observed “did not reach our expectations.”
Just a few days ago, Roche touted Enspryng’s “best-in-disease potential in MG” during a neurology investor event, a company presentation shows. At that time, Roche highlighted the remaining unmet need in gMG, including about 10% to 30% of patients who fail on standard-of-care therapies, and at least 60% of patients on novel biologics who couldn’t achieve stable remission.
Roche’s labeling of the Enspryng’s data as weak was a relief for other developers of biologics for gMG, such as Johnson & Johnson, UCB and argenx. As Enspryng was tested under the skin once every four weeks in LUMINESCE, it could have held a convenience edge over other once-weekly regimens given either subcutaneously or through intravenous infusions.
While Enspryng inhibits IL-6 signaling, UCB’s Rystiggo and argenx’s Vyvgart are anti-FcRn antibodies. And J&J just reported a positive outcome for the anti-FcRn candidate nipocalimabin a phase 3 gMG trial, although the magnitude of improvement remains under wraps. AstraZeneca’s Soliris and long-acting Ultomiris are C5 inhibitorsC5 inhibitors.
Originally approved by the FDA in late 2021 as the first FcRn inhibitorFcRn inhibitor, Vyvgart last year generated $1.2 billion in sales from gMG. Enspryng, with a 2020 FDA nod in certain patients with the neurological autoimmune disease of neuromyelitis optica spectrum disorder, only generated 256 Swiss francs ($285 million) in 2023 sales.
Despite the disappointing gMG results, Roche remains committed to developing Enspryng in other neurological autoimmune and inflammatory diseases. Phase 3 trials are ongoing for Enspryng in myelin oligodendrocyte glycoprotein-associated disorder and autoimmune encephalitis, as well as thyroid eye disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.